Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial

PURPOSE: This open-label phase III trial evaluated efficacy and tolerability of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy. PATIENTS AND METHODS: Patients were randomly assigned in a 1:1 ratio to linifanib 17.5 mg once daily or...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Oncol
Auteurs principaux: Cainap, Calin, Qin, Shukui, Huang, Wen-Tsung, Chung, Ik Joo, Pan, Hongming, Cheng, Ying, Kudo, Masatoshi, Kang, Yoon-Koo, Chen, Pei-Jer, Toh, Han-Chong, Gorbunova, Vera, Eskens, Ferry A.L.M., Qian, Jiang, McKee, Mark D., Ricker, Justin L., Carlson, Dawn M., El-Nowiem, Saied
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2015
Sujets:
ORIGINAL REPORTS
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4279237/
https://ncbi.nlm.nih.gov/pubmed/25488963
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.54.3298
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires